The global oral anticoagulants market size was worth around $18B in 2021 and is predicted to grow to around $34.1B by 2028 with a compound annual growth rate (CAGR) of roughly 9.6% between 2022 and 2028, according to a report by Facts and Factors.
The preferred method of drug delivery in the pharmaceutical industry is oral administration. Oral anticoagulants, often known as blood thinners, are medications that function in conjunction with the body's natural blood-thickening system to prevent and cure unusual blood clots. Patients who have blood clots in the legs (also known as deep vein thrombosis or DVT) or in the lungs (also known as pulmonary embolism or PE), different types of blood clusters in the veins, an irregular heartbeat known as atrial fibrillation that increases the risk of stroke, and mechanical heart valves are all treated with oral anticoagulants.
Oral anticoagulants have increased their market share significantly in recent years due to pharmaceutical scientists' improved and full understanding of the biochemical and physicochemical properties and improved patient compliance. Oral anticoagulants have become a popular substitute for traditional pills and capsules. Three novel oral anticoagulant medications have received FDA approval in recent years: Pradaxa (dabigatran), Xarelto (rivaroxaban), and Eliquis (apixaban). All three are "blood thinners," like warfarin, that lower the risk of stroke associated with atrial fibrillation but also induce bleeding.